Background
Primary aldosteronism (PA) is estimated to be responsible for 5-10% of all cases of hypertension (HTN) 1. The current gold standard test for determining lateralisation in PA is adrenal vein sampling (AVS). 11 C-Metomidate PET/CT (MTO-PET) has recently emerged as a potential non-invasive alternative to AVS 2 . As 11 C-Metomidate is concentrated within 'hyper-functioning' nodules, MTO-PET potentially not only identifies the side, but the exact site of aldosterone hypersecretion, thus raising the possibility of more targeted surgical intervention.
Case Report
A 45-year-old man was noted to have HTN and hypokalaemia following a myocardial infarction. He required four anti-hypertensive agents to achieve BP control. His plasma aldosterone was elevated with a suppressed plasma renin (off interfering medications), and aldosterone did not adequately decrease following saline suppression, confirming the diagnosis of PA. Adrenal CT and MRI did not convincingly demonstrate a lesion. He underwent AVS, but the result was inconclusive (right adrenal vein not cannulated). MTO-PET revealed focally increased tracer uptake in a sub-centimetre nodule in the left adrenal gland.
Treatment and outcome

Conclusion
This case highlights the ability of MTO-PET to not only lateralise, but actually localise the site of aldosterone hypersecretion, and thereby guide selective removal of a Conn's adenoma with sparing of the adjacent normal adrenal gland. 
